December 27, 2017 / 7:04 AM / 25 days ago

BRIEF-Herantis Pharma Reports Delay Of Lymfactin Phase 1 Study

Dec 27 (Reuters) - Herantis Pharma Oyj:

* REG-HERANTIS PHARMA EXPANDS ON TIMELINE FOR LYMFACTIN STUDIES

* ANNOUNCES A SLIGHT DELAY IN COMPLETING PATIENT RECRUITMENT IN CLINICAL PHASE 1 STUDY WITH LYMFACTIN​

* ‍PATIENT RECRUITMENT IS EXPECTED TO BE COMPLETED IN Q1 OF 2018 INSTEAD OF BY END OF 2017​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below